Thomas Jaenisch
Concepts (312)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Zika Virus Infection | 30 | 2026 | 168 | 6.140 |
Why?
| | Dengue | 26 | 2025 | 89 | 5.420 |
Why?
| | Zika Virus | 26 | 2026 | 132 | 4.030 |
Why?
| | Pregnancy Complications, Infectious | 13 | 2026 | 428 | 2.180 |
Why?
| | Disease Outbreaks | 9 | 2024 | 422 | 1.530 |
Why?
| | Microcephaly | 9 | 2023 | 103 | 1.440 |
Why?
| | Epidemics | 5 | 2026 | 98 | 1.100 |
Why?
| | Dengue Virus | 12 | 2024 | 58 | 1.070 |
Why?
| | Maternal Exposure | 2 | 2026 | 213 | 0.990 |
Why?
| | Chikungunya Fever | 9 | 2026 | 84 | 0.970 |
Why?
| | Seroepidemiologic Studies | 16 | 2025 | 172 | 0.970 |
Why?
| | Communicable Diseases | 6 | 2024 | 163 | 0.950 |
Why?
| | Malaria | 3 | 2022 | 73 | 0.880 |
Why?
| | Public Health | 7 | 2026 | 566 | 0.880 |
Why?
| | Antibodies, Viral | 15 | 2025 | 672 | 0.830 |
Why?
| | Brazil | 16 | 2026 | 180 | 0.800 |
Why?
| | Congenital Abnormalities | 2 | 2021 | 104 | 0.750 |
Why?
| | Malaria, Falciparum | 3 | 2012 | 33 | 0.730 |
Why?
| | Protein Array Analysis | 2 | 2020 | 56 | 0.730 |
Why?
| | Masks | 1 | 2022 | 70 | 0.720 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2026 | 675 | 0.710 |
Why?
| | Endpoint Determination | 2 | 2018 | 83 | 0.690 |
Why?
| | Clinical Trials as Topic | 3 | 2025 | 1054 | 0.650 |
Why?
| | Anemia | 3 | 2022 | 188 | 0.650 |
Why?
| | Biomedical Research | 4 | 2026 | 710 | 0.620 |
Why?
| | Dengue Vaccines | 2 | 2018 | 11 | 0.610 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2019 | 20 | 0.580 |
Why?
| | Humans | 94 | 2026 | 144957 | 0.580 |
Why?
| | Politics | 3 | 2025 | 97 | 0.570 |
Why?
| | Information Dissemination | 3 | 2026 | 223 | 0.570 |
Why?
| | Severe Dengue | 5 | 2022 | 10 | 0.560 |
Why?
| | Latin America | 8 | 2024 | 94 | 0.530 |
Why?
| | Plasmodium falciparum | 3 | 2019 | 39 | 0.510 |
Why?
| | Parasitemia | 2 | 2021 | 15 | 0.490 |
Why?
| | Meta-Analysis as Topic | 3 | 2025 | 174 | 0.450 |
Why?
| | Child Health | 1 | 2016 | 157 | 0.430 |
Why?
| | Fever | 3 | 2026 | 312 | 0.420 |
Why?
| | Capital Financing | 1 | 2013 | 7 | 0.410 |
Why?
| | Pregnancy | 15 | 2026 | 7191 | 0.410 |
Why?
| | Chikungunya virus | 7 | 2026 | 86 | 0.400 |
Why?
| | Prospective Studies | 16 | 2023 | 7997 | 0.400 |
Why?
| | Peptides | 1 | 2019 | 998 | 0.380 |
Why?
| | Young Adult | 23 | 2026 | 14126 | 0.380 |
Why?
| | Communicable Diseases, Emerging | 2 | 2025 | 38 | 0.370 |
Why?
| | Female | 44 | 2026 | 78376 | 0.370 |
Why?
| | Child | 26 | 2026 | 22657 | 0.360 |
Why?
| | Genetic Variation | 2 | 2017 | 984 | 0.350 |
Why?
| | Sexual Partners | 2 | 2024 | 192 | 0.340 |
Why?
| | Mosquito Vectors | 4 | 2019 | 28 | 0.340 |
Why?
| | Emergency Responders | 2 | 2021 | 37 | 0.330 |
Why?
| | Bayes Theorem | 2 | 2022 | 433 | 0.310 |
Why?
| | Aedes | 4 | 2019 | 65 | 0.310 |
Why?
| | Cohort Studies | 10 | 2026 | 5965 | 0.300 |
Why?
| | Adolescent | 22 | 2026 | 22453 | 0.300 |
Why?
| | Hemoglobins | 2 | 2022 | 384 | 0.300 |
Why?
| | Alphavirus | 2 | 2019 | 22 | 0.300 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2021 | 193 | 0.300 |
Why?
| | Delivery of Health Care | 1 | 2016 | 947 | 0.300 |
Why?
| | Alphavirus Infections | 2 | 2019 | 45 | 0.290 |
Why?
| | Pandemics | 5 | 2025 | 1695 | 0.290 |
Why?
| | Causality | 3 | 2024 | 126 | 0.280 |
Why?
| | Serologic Tests | 4 | 2021 | 53 | 0.280 |
Why?
| | Asia | 5 | 2023 | 70 | 0.280 |
Why?
| | Male | 33 | 2026 | 72406 | 0.270 |
Why?
| | Adult | 27 | 2026 | 40506 | 0.270 |
Why?
| | South America | 2 | 2025 | 57 | 0.270 |
Why?
| | Viremia | 3 | 2024 | 158 | 0.260 |
Why?
| | Immunity, Humoral | 2 | 2019 | 120 | 0.250 |
Why?
| | Incidence | 7 | 2020 | 2883 | 0.250 |
Why?
| | Virus Diseases | 2 | 2019 | 216 | 0.250 |
Why?
| | Infant, Newborn | 12 | 2022 | 6434 | 0.240 |
Why?
| | Pneumonia | 1 | 2012 | 631 | 0.240 |
Why?
| | Infant | 11 | 2021 | 10039 | 0.240 |
Why?
| | Orthobunyavirus | 1 | 2025 | 8 | 0.240 |
Why?
| | Cluster Analysis | 2 | 2019 | 521 | 0.240 |
Why?
| | Bunyaviridae Infections | 1 | 2025 | 15 | 0.230 |
Why?
| | Child, Preschool | 15 | 2026 | 11799 | 0.230 |
Why?
| | Arthralgia | 1 | 2026 | 61 | 0.220 |
Why?
| | Prevalence | 6 | 2026 | 2836 | 0.220 |
Why?
| | Sexually Transmitted Diseases, Viral | 2 | 2024 | 11 | 0.220 |
Why?
| | Mass Media | 1 | 2025 | 41 | 0.220 |
Why?
| | Africa South of the Sahara | 2 | 2022 | 53 | 0.220 |
Why?
| | Research Design | 4 | 2025 | 1137 | 0.220 |
Why?
| | Middle Aged | 18 | 2026 | 35928 | 0.210 |
Why?
| | Malaria Vaccines | 2 | 2019 | 11 | 0.210 |
Why?
| | Viral Nonstructural Proteins | 2 | 2018 | 67 | 0.210 |
Why?
| | Arbovirus Infections | 1 | 2024 | 20 | 0.210 |
Why?
| | Arboviruses | 2 | 2024 | 14 | 0.210 |
Why?
| | Risk Factors | 11 | 2026 | 10792 | 0.200 |
Why?
| | Severity of Illness Index | 2 | 2014 | 2925 | 0.200 |
Why?
| | Research Personnel | 1 | 2026 | 186 | 0.200 |
Why?
| | Semantics | 1 | 2024 | 100 | 0.200 |
Why?
| | Linear Models | 2 | 2023 | 854 | 0.200 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2021 | 104 | 0.200 |
Why?
| | O'nyong-nyong Virus | 2 | 2019 | 4 | 0.190 |
Why?
| | Attitude of Health Personnel | 1 | 2011 | 1186 | 0.190 |
Why?
| | Neurodevelopmental Disorders | 1 | 2026 | 227 | 0.190 |
Why?
| | Cytokines | 3 | 2021 | 2065 | 0.190 |
Why?
| | Toxoplasmosis | 2 | 2019 | 43 | 0.190 |
Why?
| | Oligohydramnios | 1 | 2022 | 12 | 0.190 |
Why?
| | Personal Protective Equipment | 1 | 2022 | 57 | 0.180 |
Why?
| | Mosquito Control | 2 | 2014 | 29 | 0.180 |
Why?
| | World Health Organization | 4 | 2018 | 105 | 0.180 |
Why?
| | Vietnam | 4 | 2024 | 30 | 0.180 |
Why?
| | Social Media | 1 | 2025 | 171 | 0.180 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 129 | 0.180 |
Why?
| | RNA, Viral | 4 | 2022 | 688 | 0.180 |
Why?
| | Antibodies, Neutralizing | 2 | 2022 | 341 | 0.180 |
Why?
| | Endemic Diseases | 3 | 2024 | 33 | 0.180 |
Why?
| | Algorithms | 2 | 2022 | 1839 | 0.180 |
Why?
| | Ebolavirus | 1 | 2022 | 89 | 0.180 |
Why?
| | Delphi Technique | 2 | 2025 | 331 | 0.170 |
Why?
| | Epitopes | 2 | 2020 | 485 | 0.170 |
Why?
| | Motivation | 1 | 2026 | 610 | 0.170 |
Why?
| | Tanzania | 2 | 2012 | 73 | 0.170 |
Why?
| | Chemokine CXCL10 | 1 | 2021 | 39 | 0.160 |
Why?
| | Health Policy | 2 | 2014 | 401 | 0.160 |
Why?
| | Risk | 5 | 2021 | 911 | 0.160 |
Why?
| | Epitope Mapping | 1 | 2020 | 61 | 0.160 |
Why?
| | Transients and Migrants | 1 | 2020 | 27 | 0.160 |
Why?
| | Longitudinal Studies | 5 | 2026 | 2947 | 0.160 |
Why?
| | Parvovirus B19, Human | 1 | 2019 | 3 | 0.160 |
Why?
| | Rubella virus | 1 | 2019 | 7 | 0.160 |
Why?
| | Toxoplasma | 1 | 2019 | 49 | 0.150 |
Why?
| | Case-Control Studies | 4 | 2021 | 3608 | 0.150 |
Why?
| | Emigration and Immigration | 1 | 2020 | 66 | 0.150 |
Why?
| | Hydrocephalus | 1 | 2020 | 111 | 0.150 |
Why?
| | Biomarkers | 5 | 2023 | 4275 | 0.150 |
Why?
| | Diagnosis, Differential | 3 | 2021 | 1495 | 0.150 |
Why?
| | Antibodies, Protozoan | 1 | 2019 | 41 | 0.140 |
Why?
| | Hospitalization | 2 | 2020 | 2434 | 0.140 |
Why?
| | Cytomegalovirus | 1 | 2019 | 168 | 0.140 |
Why?
| | Africa | 2 | 2019 | 116 | 0.140 |
Why?
| | Phylogeny | 3 | 2019 | 1019 | 0.140 |
Why?
| | Automation | 1 | 2019 | 102 | 0.140 |
Why?
| | Peptide Library | 1 | 2019 | 95 | 0.140 |
Why?
| | Genotype | 4 | 2017 | 1835 | 0.140 |
Why?
| | Viral Load | 1 | 2021 | 526 | 0.140 |
Why?
| | Serotyping | 1 | 2018 | 32 | 0.140 |
Why?
| | Premature Birth | 1 | 2022 | 380 | 0.140 |
Why?
| | Animals | 14 | 2026 | 38109 | 0.140 |
Why?
| | Violence | 1 | 2021 | 281 | 0.140 |
Why?
| | Serum | 1 | 2018 | 59 | 0.130 |
Why?
| | Phosphoinositide Phospholipase C | 1 | 2017 | 5 | 0.130 |
Why?
| | C-Reactive Protein | 1 | 2020 | 417 | 0.130 |
Why?
| | Maternal-Fetal Exchange | 1 | 2018 | 169 | 0.130 |
Why?
| | Global Health | 3 | 2019 | 401 | 0.130 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2017 | 39 | 0.130 |
Why?
| | Peptide Mapping | 1 | 2017 | 63 | 0.130 |
Why?
| | Spatio-Temporal Analysis | 3 | 2025 | 39 | 0.120 |
Why?
| | Blood Donors | 1 | 2018 | 143 | 0.120 |
Why?
| | Sequence Homology | 1 | 2016 | 43 | 0.120 |
Why?
| | Caribbean Region | 3 | 2020 | 30 | 0.120 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 4 | 2021 | 851 | 0.120 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2017 | 202 | 0.120 |
Why?
| | Viral Envelope Proteins | 1 | 2016 | 98 | 0.110 |
Why?
| | Antigens | 1 | 2017 | 347 | 0.110 |
Why?
| | Clinical Protocols | 1 | 2016 | 282 | 0.110 |
Why?
| | Serogroup | 3 | 2021 | 44 | 0.110 |
Why?
| | Models, Theoretical | 1 | 2018 | 582 | 0.110 |
Why?
| | Antigens, Viral | 2 | 2018 | 182 | 0.110 |
Why?
| | Fluid Therapy | 1 | 2016 | 147 | 0.110 |
Why?
| | Antibodies | 1 | 2017 | 403 | 0.110 |
Why?
| | Environment | 1 | 2016 | 305 | 0.100 |
Why?
| | European Union | 1 | 2013 | 12 | 0.100 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3415 | 0.100 |
Why?
| | Residence Characteristics | 1 | 2017 | 378 | 0.100 |
Why?
| | Mental Health | 1 | 2020 | 792 | 0.100 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2021 | 893 | 0.100 |
Why?
| | Immunoglobulin M | 3 | 2021 | 284 | 0.100 |
Why?
| | Data Interpretation, Statistical | 2 | 2025 | 372 | 0.100 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 824 | 0.100 |
Why?
| | Surveys and Questionnaires | 3 | 2026 | 6053 | 0.090 |
Why?
| | Disease Management | 1 | 2016 | 647 | 0.090 |
Why?
| | Peru | 2 | 2021 | 62 | 0.080 |
Why?
| | Sensitivity and Specificity | 4 | 2019 | 1990 | 0.080 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5417 | 0.080 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2010 | 34 | 0.080 |
Why?
| | Virology | 1 | 2010 | 36 | 0.080 |
Why?
| | Indian Ocean Islands | 1 | 2010 | 1 | 0.080 |
Why?
| | Cross Reactions | 2 | 2022 | 130 | 0.080 |
Why?
| | Neutralization Tests | 2 | 2021 | 76 | 0.080 |
Why?
| | Age Factors | 2 | 2020 | 3335 | 0.080 |
Why?
| | Family Characteristics | 2 | 2021 | 197 | 0.080 |
Why?
| | Inflammation | 1 | 2021 | 2880 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 2147 | 0.080 |
Why?
| | Rural Health | 1 | 2010 | 87 | 0.080 |
Why?
| | Kinetics | 2 | 2024 | 1629 | 0.070 |
Why?
| | Mass Screening | 1 | 2018 | 1348 | 0.070 |
Why?
| | Age Distribution | 1 | 2010 | 403 | 0.070 |
Why?
| | Americas | 2 | 2019 | 26 | 0.070 |
Why?
| | Sexual Behavior | 2 | 2024 | 492 | 0.070 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1540 | 0.070 |
Why?
| | Colorado | 3 | 2026 | 4564 | 0.070 |
Why?
| | Coinfection | 2 | 2019 | 141 | 0.070 |
Why?
| | Focus Groups | 1 | 2011 | 573 | 0.070 |
Why?
| | Aged | 7 | 2026 | 25947 | 0.070 |
Why?
| | Antigens, Protozoan | 1 | 2007 | 32 | 0.060 |
Why?
| | Risk Assessment | 1 | 2017 | 3676 | 0.060 |
Why?
| | Prenatal Care | 2 | 2019 | 307 | 0.060 |
Why?
| | High-Throughput Screening Assays | 2 | 2020 | 175 | 0.060 |
Why?
| | Logistic Models | 1 | 2012 | 2119 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2026 | 5872 | 0.060 |
Why?
| | Immunoglobulin G | 2 | 2021 | 893 | 0.060 |
Why?
| | Genome, Viral | 2 | 2019 | 218 | 0.060 |
Why?
| | Urbanization | 2 | 2019 | 28 | 0.060 |
Why?
| | Microsatellite Repeats | 1 | 2007 | 157 | 0.060 |
Why?
| | Colombia | 1 | 2026 | 42 | 0.060 |
Why?
| | Ceratopogonidae | 1 | 2025 | 2 | 0.060 |
Why?
| | Insect Vectors | 1 | 2025 | 39 | 0.060 |
Why?
| | West Nile Fever | 1 | 2026 | 57 | 0.060 |
Why?
| | Cats | 1 | 2025 | 228 | 0.060 |
Why?
| | Quarantine | 1 | 2025 | 31 | 0.060 |
Why?
| | Biosurveillance | 1 | 2024 | 1 | 0.050 |
Why?
| | Tropical Climate | 2 | 2016 | 24 | 0.050 |
Why?
| | Dogs | 1 | 2025 | 438 | 0.050 |
Why?
| | Common Data Elements | 1 | 2024 | 17 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 612 | 0.050 |
Why?
| | Platelet Count | 1 | 2024 | 96 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2025 | 103 | 0.050 |
Why?
| | Europe | 1 | 2025 | 412 | 0.050 |
Why?
| | Forecasting | 1 | 2025 | 391 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1721 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 489 | 0.050 |
Why?
| | Bangladesh | 1 | 2023 | 62 | 0.050 |
Why?
| | Checklist | 1 | 2024 | 108 | 0.050 |
Why?
| | Altitude | 1 | 2007 | 473 | 0.050 |
Why?
| | Population Surveillance | 1 | 2026 | 485 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2024 | 268 | 0.040 |
Why?
| | Burkina Faso | 1 | 2021 | 7 | 0.040 |
Why?
| | Middle East | 1 | 2021 | 18 | 0.040 |
Why?
| | Publication Bias | 1 | 2021 | 17 | 0.040 |
Why?
| | Colostrum | 1 | 2021 | 3 | 0.040 |
Why?
| | Venezuela | 1 | 2021 | 8 | 0.040 |
Why?
| | Pregnancy Trimesters | 1 | 2021 | 20 | 0.040 |
Why?
| | Microspheres | 1 | 2021 | 142 | 0.040 |
Why?
| | Amniotic Fluid | 1 | 2021 | 79 | 0.040 |
Why?
| | Blood | 1 | 2021 | 109 | 0.040 |
Why?
| | Immunoassay | 1 | 2021 | 109 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2021 | 341 | 0.040 |
Why?
| | Disease Progression | 2 | 2020 | 2852 | 0.040 |
Why?
| | Parturition | 1 | 2020 | 69 | 0.040 |
Why?
| | Immunomodulation | 1 | 2021 | 101 | 0.040 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 96 | 0.040 |
Why?
| | Disease Reservoirs | 1 | 2019 | 25 | 0.040 |
Why?
| | Genes, Viral | 1 | 2019 | 90 | 0.040 |
Why?
| | Chronic Disease | 1 | 2026 | 1813 | 0.040 |
Why?
| | Geography, Medical | 1 | 2019 | 11 | 0.040 |
Why?
| | Pathology, Molecular | 1 | 2019 | 25 | 0.040 |
Why?
| | Zoonoses | 1 | 2019 | 36 | 0.040 |
Why?
| | Pregnancy Outcome | 1 | 2022 | 476 | 0.040 |
Why?
| | Pilot Projects | 1 | 2025 | 1890 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2024 | 17101 | 0.040 |
Why?
| | Primates | 1 | 2019 | 132 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2021 | 1054 | 0.030 |
Why?
| | Bolivia | 1 | 2018 | 61 | 0.030 |
Why?
| | Computer Simulation | 1 | 2022 | 1026 | 0.030 |
Why?
| | Viral Plaque Assay | 1 | 2017 | 29 | 0.030 |
Why?
| | Volunteers | 1 | 2018 | 39 | 0.030 |
Why?
| | Basic Reproduction Number | 1 | 2017 | 6 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 286 | 0.030 |
Why?
| | Poliovirus Vaccines | 1 | 2017 | 6 | 0.030 |
Why?
| | Parent-Child Relations | 1 | 2020 | 270 | 0.030 |
Why?
| | Binding Sites, Antibody | 1 | 2017 | 41 | 0.030 |
Why?
| | United States | 2 | 2025 | 15988 | 0.030 |
Why?
| | Culicidae | 1 | 2017 | 33 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2021 | 8279 | 0.030 |
Why?
| | Time Factors | 2 | 2020 | 7183 | 0.030 |
Why?
| | Molecular Epidemiology | 1 | 2017 | 73 | 0.030 |
Why?
| | Cell Surface Display Techniques | 1 | 2017 | 13 | 0.030 |
Why?
| | Phylogeography | 1 | 2017 | 55 | 0.030 |
Why?
| | Iron | 1 | 2019 | 359 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2017 | 181 | 0.030 |
Why?
| | Climate Change | 1 | 2019 | 199 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2018 | 983 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1660 | 0.030 |
Why?
| | Bacterial Infections | 1 | 2018 | 246 | 0.030 |
Why?
| | Enterovirus | 1 | 2017 | 82 | 0.030 |
Why?
| | Capsid Proteins | 1 | 2017 | 95 | 0.030 |
Why?
| | Pacific Islands | 1 | 2015 | 5 | 0.030 |
Why?
| | Immunization | 1 | 2018 | 374 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2021 | 717 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2018 | 744 | 0.030 |
Why?
| | Inpatients | 1 | 2020 | 546 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 378 | 0.030 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2015 | 131 | 0.030 |
Why?
| | Hospitals | 1 | 2020 | 732 | 0.030 |
Why?
| | Models, Statistical | 1 | 2019 | 682 | 0.030 |
Why?
| | Travel | 1 | 2015 | 136 | 0.030 |
Why?
| | Shock | 1 | 2016 | 108 | 0.030 |
Why?
| | Blood Vessels | 1 | 2016 | 171 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2014 | 134 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2017 | 2157 | 0.020 |
Why?
| | Quality Control | 1 | 2013 | 163 | 0.020 |
Why?
| | Rain | 1 | 2013 | 49 | 0.020 |
Why?
| | Antiviral Agents | 1 | 2018 | 768 | 0.020 |
Why?
| | Thrombocytopenia | 1 | 2014 | 205 | 0.020 |
Why?
| | Cell Line | 1 | 2018 | 2882 | 0.020 |
Why?
| | Computational Biology | 1 | 2017 | 681 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 4293 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 1524 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2017 | 1407 | 0.020 |
Why?
| | Temperature | 1 | 2013 | 679 | 0.020 |
Why?
| | Hemorrhage | 1 | 2014 | 809 | 0.020 |
Why?
| | Vaccination | 1 | 2017 | 1423 | 0.020 |
Why?
| | Merozoite Surface Protein 1 | 1 | 2007 | 4 | 0.020 |
Why?
| | Zimbabwe | 1 | 2007 | 76 | 0.020 |
Why?
| | Databases, Factual | 1 | 2013 | 1486 | 0.020 |
Why?
| | Protozoan Proteins | 1 | 2007 | 93 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2014 | 1563 | 0.010 |
Why?
| | Mutation | 1 | 2017 | 4099 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2018 | 11695 | 0.010 |
Why?
|
|
Jaenisch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|